Dr Jens Würthner | Head of Clinical Development – EU
ADC Therapeutics

Dr Jens Würthner, Head of Clinical Development – EU, ADC Therapeutics

Jens Würthner, MD PhD, is a physician scientist and currently holds the position of Head of Clinical Development – EU for ADC Therapeutics in Lausanne, Switzerland. He is a fellow of the Faculty of Pharmaceutical Medicine, UK and visiting senior lecturer for Kings College, School of Biomedical Sciences, in London.
Dr. Würthner qualified as a physician in Hamburg, Germany, and entered clinical oncology at the University of Freiburg, followed by cancer research at the National Institutes of Health, Bethesda, USA. During the latter he identified a novel class of proteins, which he demonstrated to be essential components of the TGF-beta signaling cascade.
After joining the pharmaceutical industry, Dr. Würthner worked in early clinical development for AstraZeneca, GlaxoSmithKline and Novartis across oncology, infection and immunology. His most significant contributions to the field were in translational and early clinical development of Olaparib in ovarian cancer, of Cytofab and GSK1995057 in sepsis and acute lung injury, respectively, and of CGM097 and HDM201, two MDM2 inhibitors, across several solid and hematological tumor indications.

Appearances:



EAC 2017 Day 2, Wednesday 1st November 2017 @ 14:35

Bringing PBD-ADCs to the clinic

  • Introduction to PBDs
  • Preclinical data on ADCs targeting CD19, CD25, CD22 and HER2
  • Translation to the clinic : PBD PD biomarkers
  • Clinical validation: Current landscape of advanced PBD-ADCs
  • Clinical plans and current status of the ADC-Therapeutics pipeline
 

back to speakers